 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Mirae Asset Group has established a venture capital specializing in pharmaceutical bio in the U.S. and has begun full-fledged activities.
According to Bizwatch on the 19th, Mirae Asset Capital and Mirae Asset Asset Management established 'Mirae Asset Capital Life Science', a US bio-specialized venture investment company, in the form of a joint venture last year. The company recently finished recruiting its first fund investor worth $ 5 million (6.6 billion won) and held a "kick-off meeting" in New York on the 16th. Chairman Park attended the meeting in person.
Mirae Asset Capital Life Science is the first bio-venture established by Mirae Asset Group in the United States.
According to PitchBook, a global market research firm, US venture capital raised $ 67 billion (about 90 trillion won) last year. As the COVID-19 calms down, huge amounts of money are still being invested in the bio sector, even though it was the lowest since 2015.
Earlier, Park said in 2016 that he will invest a total of 10 trillion won, 1 trillion won per year in venture companies in new growth engines such as bio and healthcare over the next 10 years. Mirae Asset Capital Life Science cut off its first tape this year.
Of the first five million dollars recruited, 25% set up a fund after completing a capital call (investment request). Mirae Asset Capital Life Science is a leading investor and plans to invest the amount mainly in overseas bio companies.
AlphaBIZ 김지선(stockmk2020@alphabiz.co.kr)
